Lee Ainslie Incyte Corp Transaction History

Maverick Capital LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $16,686 - $20,416	-243 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $698,862 - $765,887	-8,750 Reduced 97.3%	243 $20,000
Q1 2021 May 17, 2021	SELL	$76.02 - $100.5 $29,799 - $39,396	-392 Reduced 4.18%	8,993 $731,000
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $757,744 - $916,914	9,385 New	9,385 $816,000
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $794,310 - $1.04 Million	-10,875 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $791,917 - $940,905	10,875 New	10,875 $807,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.